

## ASX ANNOUNCEMENT

### DISPATCH OF RIGHTS ISSUE DOCUMENTATION COMPLETED

**SYDNEY, Friday, 12 March 2021: Cellmid Limited (ASX: CDY)** is pleased to advise that in accordance with the Rights Issue timetable included in the Rights Issue Prospectus announced to the ASX on Monday, 8 March 2021, dispatch of the Prospectus and personalized Entitlement & Acceptance Form to eligible shareholders was completed today.

Rights trading ends on 19 March 2021 and the Rights Issue closes on 26 March 2021 (unless extended in accordance with the Listing Rules). Shareholders may in addition to their entitlement apply for shortfall.

Eligible shareholders should consider the Prospectus in deciding whether to acquire securities under the Rights Issue and will need to follow the instructions on the Entitlement and Acceptance form that accompanied the Prospectus.

Pursuant to ASX Listing Rule 7.7.1(b) the Company has also today dispatched a letter to ineligible shareholders, a copy of this letter is enclosed.

Approved for release by Maria Halasz, CEO and Managing Director.

End

Contact:

Maria Halasz, CEO

T +612 9221 6830



@mariahalasz

#### **Cellmid Limited (ASX: CDY)**

Cellmid is a health and beauty-tech business growing shareholder value through the development, global distribution and sales of its proprietary brands of differentiated, clinically validated longevity and anti-aging solutions. Advangen Limited is Cellmid's wholly owned subsidiary engaged in the development and sale of first in class, best in class, clinically validated products for hair, skin and body. For further information, please see [www.cellmid.com.au](http://www.cellmid.com.au) and [www.evolisproducts.com.au](http://www.evolisproducts.com.au).

#### **Forward looking statements**

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as the availability of resources, regulatory environment, the results of marketing and sales activities and competition.

12 March 2021

Dear Shareholders,

**Cellmid Limited – Notice to Ineligible Shareholders**

1. On 8 March 2021 Cellmid Limited (ACN 111 304 119) (**CDY** or the **Company**) announced that it has launched a Renounceable Rights Issue to raise up to approximately \$3.8 million (**the Rights Issue** or **Entitlement Offer**).
2. Eligible shareholders can subscribe for 2 New Shares for every 5 existing Shares held at 5.00pm (AEDT) on 11 March 2021 (**Record Date**) at the price of \$0.075 per New Share (**Entitlements**). For every 2 New Shares issued, Shareholders will receive a new option for which the Company will seek quotation (**New Options**) with 18 cents exercise price each and an expiry date of 2 years from issue.
3. The Company will offer the New Shares and New Options under a prospectus lodged with ASIC on 8 March 2021 and released to ASX which is available to view on ASX's website ([www.asx.com.au](http://www.asx.com.au)).
4. Fractional Entitlements will be rounded down to the nearest whole number of New Shares, and holdings on different registers or sub-registers will not be aggregated to calculate Entitlements.
5. The Company expects that the Entitlement Offer will be conducted as follows:

Ex-date – Shares trade ex Entitlement (Ex-Date) Rights trading commences on a deferred settlement basis	10 March 2021
Record date to determine Entitlement (Record Date)	5pm AEDT, 11 March 2021
Prospectus with Entitlement and Acceptance Form dispatched Offer opens for receipt of Applications	12 March 2021
Rights trading ends	19 March 2021
Closing date for acceptances	26 March 2021
Announce the results of the issue	31 March 2021
Issue of New Shares Dispatch of shareholding statements	1 April 2021
Normal trading of New Shares expected to commence	6 April 2021
Last date to issue Shortfall Shares (see section 8.6)	25 June 2021

This timetable is indicative only and subject to change, subject to the Listing Rules.

6. The capital structure of the Company following completion of the Rights Issue is expected to be as follows (ignoring the effect of rounding Entitlements):

	Underwritten Amount	Full Subscription
Shares currently on issue	127,212,303	127,212,303
Total Options currently on issue	10,689,400	10,689,400
New Shares offered under this Prospectus, on a 2 for 5 basis <sup>1</sup>	40,000,000	50,884,921
New Options offered under this Prospectus, being 1 New Option for every 2 new Shares issued <sup>1, 2</sup>	20,000,000	25,442,461
Issue price per New Share	\$0.075	\$0.075
Amount raised under this Prospectus (before costs) <sup>1</sup>	\$3,000,000	\$3,816,369
Total Shares on issue following the Offer	167,212,303	178,097,224

<sup>1</sup> This assumes no further securities are issued prior to the Record Date.

<sup>2</sup> The Company has also agreed to issue Mahe Capital 1 New Option for every \$2 raised under the Offer

7. The Company has determined pursuant to ASX Listing Rule 7.7.1(a) and section 9A(3) of the Corporations Act that it would be unreasonable to make the Entitlement Offer to shareholders with a registered address outside Australia or New Zealand. Accordingly and as you have a registered address outside Australia or New Zealand on the Record Date, this letter is to inform you that the Entitlement Offer is not made to you and you are not eligible to apply for the New Shares. You are not required to do anything in response to this letter.
8. As the Rights Issue is renounceable, for the purposes of Listing Rule 7.7.1(c), the Company has appointed Mahe Capital Limited (**Nominee**) as nominee to sell Ineligible Shareholders' Entitlements should they be eligible. The Nominee will have the absolute and sole discretion to determine the timing and price at which the Entitlements may be sold and the manner of any such sale. Any interest earned on the proceeds of the sale of these Entitlements will firstly be applied against expenses of such sale, including brokerage, and any balance will accrue to Ineligible Shareholders.
9. The net proceeds of the sale of these Entitlements will then be forwarded by the Company as soon as practicable to the Ineligible Shareholders, in proportion to their share of such Entitlements (after deducting brokerage commission and other expenses). If any such net proceeds of sale are less than the reasonable costs that would be incurred by the Company for distributing those proceeds, such proceeds may be retained by the Company. There is no guarantee that the Nominee will be able to sell Entitlements of

Ineligible Shareholders on ASX and Ineligible Shareholders may receive no value for the Entitlements. Both the Company and the Nominee take no responsibility for the outcome of the sale of such Entitlements or the failure to sell such Entitlements.

10. If you have any queries, please contact Lee Tamplin, company secretary, on +61 2 8072 1429 Lee.Tamplin@automicgroup.com.au between 9:00am and 5:00pm (AEDT) Monday to Friday, alternatively, consult your stockbroker, solicitor, accountant or other professional financial adviser.

On behalf of the directors, I thank you for your continued support of the Company.

Yours faithfully

Ms Maria Halasz  
Managing Director  
Cellmid Limited

**Important notices**

This letter does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to in this letter have not been and will not be registered under the United States Securities Act of 1933 (the 'US Securities Act'), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold, directly or indirectly, within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available.